Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Hepatitis

ClinicalTrials.gov lists 4,422 trials for Hepatitis or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 190.

MeSH D006505 Digestive System Diseases C06
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 497 Phase 1/2 Phase 1/2 108 Phase 2 Phase 2 697 Phase 2/3 Phase 2/3 74 Phase 3 Phase 3 649 Phase 4 Phase 4 684 Not applicable Not applicable 575 Observational Observational 1,128 Phase 1 Phase 1 497 Phase 1/2 Phase 1/2 108 Phase 2 Phase 2 697 Phase 2/3 Phase 2/3 74 Phase 3 Phase 3 649 Phase 4 Phase 4 684 Not applicable Not applicable 575 Observational Observational 1,128

Trials per phase

1 more section with rows

318 of the 4,422 trials are tagged with Hepatitis itself; the rest are tagged with a narrower condition beneath it.

Get the Hepatitis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Hepatitis trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 257

1990: 1 trials (Observational 1) 1991: 1 trials (Observational 1) 1992: 4 trials (Observational 2, Phase 2 1, Phase 1 1) 1993: 4 trials (Observational 1, Phase 3 2, Phase 2 1) 1994: 2 trials (Observational 1, Phase 3 1) 1995: 5 trials (Observational 1, Phase 4 1, Phase 3 2, Phase 2 1) 1996: 1 trials (Phase 4 1) 1997: 9 trials (Observational 2, Phase 3 4, Phase 2/3 1, Phase 2 2) 1998: 9 trials (Observational 3, Phase 3 1, Phase 2/3 1, Phase 2 4) 1999: 16 trials (Observational 6, Not applicable 1, Phase 4 1, Phase 3 6, Phase 2 1, Phase 1/2 1) 2000: 27 trials (Observational 6, Not applicable 3, Phase 4 2, Phase 3 12, Phase 2 4) 2001: 38 trials (Observational 10, Not applicable 1, Phase 4 2, Phase 3 6, Phase 2/3 1, Phase 2 13, Phase 1/2 2, Phase 1 3) 2002: 62 trials (Observational 7, Not applicable 1, Phase 4 14, Phase 3 22, Phase 2/3 3, Phase 2 15) 2003: 94 trials (Other 1, Observational 10, Not applicable 6, Phase 4 27, Phase 3 26, Phase 2 16, Phase 1/2 6, Phase 1 2) 2004: 112 trials (Observational 22, Not applicable 7, Phase 4 24, Phase 3 31, Phase 2/3 2, Phase 2 19, Phase 1/2 4, Phase 1 3) 2005: 151 trials (Observational 37, Not applicable 12, Phase 4 35, Phase 3 28, Phase 2/3 1, Phase 2 27, Phase 1/2 3, Phase 1 8) 2006: 161 trials (Observational 28, Not applicable 12, Phase 4 31, Phase 3 44, Phase 2/3 4, Phase 2 27, Phase 1/2 3, Phase 1 12) 2007: 168 trials (Observational 25, Not applicable 18, Phase 4 40, Phase 3 30, Phase 2/3 3, Phase 2 30, Phase 1/2 4, Phase 1 18) 2008: 175 trials (Observational 32, Not applicable 18, Phase 4 38, Phase 3 29, Phase 2/3 1, Phase 2 26, Phase 1/2 8, Phase 1 23) 2009: 201 trials (Observational 41, Not applicable 18, Phase 4 33, Phase 3 12, Phase 2/3 3, Phase 2 43, Phase 1/2 8, Phase 1 43) 2010: 197 trials (Observational 46, Not applicable 8, Phase 4 29, Phase 3 25, Phase 2/3 4, Phase 2 46, Phase 1/2 2, Phase 1 37) 2011: 252 trials (Observational 56, Not applicable 20, Phase 4 37, Phase 3 48, Phase 2/3 2, Phase 2 41, Phase 1/2 10, Phase 1 38) 2012: 242 trials (Observational 58, Not applicable 21, Phase 4 23, Phase 3 58, Phase 2/3 2, Phase 2 35, Phase 1/2 7, Phase 1 38) 2013: 219 trials (Observational 46, Not applicable 19, Phase 4 37, Phase 3 40, Phase 2/3 7, Phase 2 40, Phase 1/2 7, Phase 1 23) 2014: 225 trials (Observational 51, Not applicable 26, Phase 4 30, Phase 3 45, Phase 2/3 5, Phase 2 30, Phase 1/2 4, Phase 1 34) 2015: 257 trials (Observational 61, Not applicable 25, Phase 4 51, Phase 3 47, Phase 2/3 6, Phase 2 39, Phase 1/2 4, Phase 1 24) 2016: 226 trials (Observational 64, Not applicable 36, Phase 4 38, Phase 3 35, Phase 2/3 4, Phase 2 30, Phase 1/2 2, Phase 1 17) 2017: 215 trials (Observational 62, Not applicable 35, Phase 4 46, Phase 3 29, Phase 2/3 2, Phase 2 19, Phase 1/2 3, Phase 1 19) 2018: 195 trials (Observational 62, Not applicable 35, Phase 4 36, Phase 3 11, Phase 2/3 5, Phase 2 23, Phase 1/2 5, Phase 1 18) 2019: 206 trials (Observational 64, Not applicable 53, Phase 4 25, Phase 3 9, Phase 2/3 4, Phase 2 30, Phase 1/2 2, Phase 1 19) 2020: 147 trials (Observational 41, Not applicable 37, Phase 4 17, Phase 3 5, Phase 2 22, Phase 1/2 3, Phase 1 22) 2021: 132 trials (Observational 43, Not applicable 24, Phase 4 16, Phase 3 5, Phase 2/3 2, Phase 2 21, Phase 1/2 3, Phase 1 18) 2022: 144 trials (Observational 49, Not applicable 34, Phase 4 16, Phase 3 4, Phase 2/3 1, Phase 2 19, Phase 1/2 2, Phase 1 19) 2023: 131 trials (Observational 54, Not applicable 26, Phase 4 7, Phase 3 1, Phase 2/3 2, Phase 2 18, Phase 1/2 6, Phase 1 17) 2024: 135 trials (Observational 55, Not applicable 28, Phase 4 8, Phase 3 2, Phase 2/3 1, Phase 2 19, Phase 1/2 3, Phase 1 19) 2025: 108 trials (Observational 42, Not applicable 19, Phase 4 6, Phase 3 13, Phase 2/3 3, Phase 2 14, Phase 1/2 3, Phase 1 8)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 88
2025 108
2024 135
2023 131
2022 144
2021 132
2020 147
2019 206
2018 195
2017 215

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 110 trials starting in 2026 and about 110 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 175 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 3,002 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Hepatitis trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 497
Phase 1/2 108
Phase 2 697
Phase 2/3 74
Phase 3 649
Phase 4 684
Not applicable 575
Observational 1,128
Expanded access 10

How many Hepatitis trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 114
Recruiting 216
Enrolling by invitation 15
Active, not recruiting 95
Available 1

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Hepatitis trials? (11)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
GlaxoSmithKline 190
Merck Sharp & Dohme LLC 186
Gilead Sciences 171
Hoffmann-La Roche 140
Bristol-Myers Squibb 126

Showing 5 of 11 sponsors.

Start your 14-day trial Email me all 11 sponsors as a PDF

Which drugs are being tested for Hepatitis? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PEGinterferon alfa-2a 247
Entecavir 154
Peginterferon Alfa-2B 110
GS-7340 79
Daclatasvir 73

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Ribavirine 556
tenofovir disproxil fumarate 123
Sofosbuvir, Sovaldi 113
Engerix™ 67
Telaprevir 54

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Hepatitis trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Anaemia 666 135
Pneumonia 622 197
Gastroenteritis 291 104
Pyrexia 242 101
Death 222 43

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Hepatitis? (164)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Checkpoint inhibitor hepatotoxicity: pathogenesis and management. Hepatology (Baltimore, Md.) 2024 Yes
Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL-17A (LY3509754): A Phase I Randomized Placebo-Controlled Study. Clinical pharmacology and therapeutics 2024 Yes
Late-onset enteric virus infection associated with hepatitis (EVAH) in transplanted SCID patients. The Journal of allergy and clinical immunology 2023 Yes
Gut microbial trimethylamine is elevated in alcohol-associated hepatitis and contributes to ethanol-induced liver injury in mice. eLife 2022 Yes
Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens. The lancet. Gastroenterology & hepatology 2022 Yes

Showing 5 of 164 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages